GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion.
The post $10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval appeared first on MedCity News.
